Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

Gerd R Burmester, Robert Landewé, Mark C Genovese, Alan W Friedman, Nathan D Pfeifer, Nupun A Varothai, Ana P Lacerda, Gerd R Burmester, Robert Landewé, Mark C Genovese, Alan W Friedman, Nathan D Pfeifer, Nupun A Varothai, Ana P Lacerda

Abstract

Background: Adalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over 10 years and has a well-established safety profile across multiple indications.

Objective: To update adverse events (AEs) of special interest from global adalimumab clinical trials in patients with RA.

Methods: This analysis includes 15 132 patients exposed to adalimumab in global RA clinical trials. AEs of interest included overall infections, laboratory abnormalities and AEs associated with influenza vaccination. Pregnancy outcome data were collected from the Adalimumab Pregnancy Registry.

Results: Serious infections and tuberculosis occurred at a rate of 4.7 and 0.3 events/100 patient-years, respectively. Two patients experienced hepatitis B reactivation. No significant laboratory abnormalities were reported with adalimumab-plus-methotrexate compared with placebo-plus-methotrexate. Influenza-related AEs occurred in 5% of vaccinated patients compared with 14% of patients not vaccinated during the study. Relative risk of major birth defects and spontaneous abortions in adalimumab-exposed women were similar between that of unexposed women with RA and healthy women.

Conclusions: This analysis confirms and expands the known safety profile of adalimumab and reports no additional safety risk of laboratory abnormalities, hepatitis B reactivation and pregnancy outcomes, including spontaneous abortions and birth defects. The benefits of influenza vaccination are reinforced.

Trial registration numbers: NCT00195663, NCT00195702, NCT00448383, NCT00049751, NCT00234845, NCT00650390, NCT00235859, NCT00647920, NCT00649545, NCT00647491, NCT00649922, NCT00538902, NCT00420927, NCT00870467, NCT00650156, NCT00647270, NCT01185288, NCT01185301.

Keywords: Anti-TNF; Rheumatoid Arthritis; Vaccination.

Conflict of interest statement

GRB has received research grants, consulting fees and speaker's fees from AbbVie, BMS, Merck, Pfizer, Roche and UCB. RL has received consulting fees from AbbVie, Amgen, BMS, Centocor, GSK, Merck, Novartis, Pfizer, Roche, Schering-Plough, UCB and Wyeth and is owner of Rheumatology Consultancy BV. MCG has received research grants and consulting fees from AbbVie. AWF, NDP and APL are employees of AbbVie and may hold stock and/or options. NV is a former employee of AbbVie and may hold stock and/or options.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

References

    1. National Center for, Immunization Respiratory, Diseases. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1–64.
    1. Schiff MH, Burmester GR, Kent JD, et al. . Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889–94. 10.1136/ard.2005.043166
    1. Briggs GG, Polifka J, Research Committee, Organization of Teratology Information Specialists. Better data needed from pregnancy registries. Birth Defects Res Part A Clin Mol Teratol 2009;85:109–11. 10.1002/bdra.20551
    1. Breedveld FC, Weisman MH, Kavanaugh AF, et al. . The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37. 10.1002/art.21519
    1. Kavanaugh A, Fleischmann RM, Emery P, et al. . Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64–71. 10.1136/annrheumdis-2011-201247
    1. Keystone EC, Kavanaugh AF, Sharp JT, et al. . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11. 10.1002/art.20217
    1. Keystone EC, van der Heijde D, Kavanaugh A, et al. . Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013;40:1487–97. 10.3899/jrheum.120964
    1. Hyoun SC, Običan SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res Part A Clin Mol Teratol 2012;94:187–207. 10.1002/bdra.23003
    1. Galloway JB, Hyrich KL, Mercer LK, et al. . Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124–31. 10.1093/rheumatology/keq242
    1. Kay J, Fleischmann R, Keystone E, et al. . Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2015;74:538–46. 10.1136/annrheumdis-2013-204195
    1. Listing J, Strangfeld A, Kary S, et al. . Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403–12. 10.1002/art.21386
    1. Weinblatt ME, Bathon JM, Kremer JM, et al. . Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:373–82.
    1. Burmester GR, Panaccione R, Gordon KB, et al. . Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517–24. 10.1136/annrheumdis-2011-201244
    1. Winthrop KL, Baddley JW, Chen L, et al. . Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887–95. 10.1001/jama.2013.1099
    1. Galloway JB, Mercer LK, Moseley A, et al. . Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72:229–34. 10.1136/annrheumdis-2011-201108
    1. Zisman D, Bitterman H, Shalom G, et al. . Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis 2016;75:131–5. 10.1136/annrheumdis-2013-205148
    1. Burmester GR, Kivitz AJ, Kupper H, et al. . Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037–44. 10.1136/annrheumdis-2013-204769
    1. Humira [package insert]. North Chicago, IL, USA: AbbVie, 2014.
    1. Berthelot JM, De Bandt M, Goupille P, et al. . Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76:28–34. 10.1016/j.jbspin.2008.04.016
    1. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. . Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014;43:78–84. 10.1016/j.reprotox.2013.11.004
    1. Roux CH, Brocq O, Breuil V, et al. . Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007;46:695–8. 10.1093/rheumatology/kel400

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit